Clinical experience with intravenous Augmentin in the treatment of paediatric infections

J Int Med Res. 1986;14(3):153-7. doi: 10.1177/030006058601400307.

Abstract

The clinical efficacy of intravenous Augmentin (a formulation containing amoxycillin plus clavulanic acid) was investigated in an open study in fifty-eight children with a mean age of 6 years (range 1-15 years). The normal dosage was in the range 100-200 mg/kg/day Augmentin, administered parenterally by short i.v. infusion in 3 or 4 divided doses. Most patients were hospitalised for lower respiratory tract infections. Complete clinical cure or distinct clinical improvement was achieved in all assessable cases. Bacteriological success was obtained in 92% of the assessable cases. In two patients, mild, transient exanthema was noted after i.v. Augmentin was replaced by oral Augmentin. No additional therapeutic measures were required.

MeSH terms

  • Adolescent
  • Amoxicillin / administration & dosage
  • Amoxicillin / adverse effects
  • Amoxicillin / therapeutic use*
  • Amoxicillin-Potassium Clavulanate Combination
  • Bacterial Infections / drug therapy*
  • Child
  • Child, Preschool
  • Clavulanic Acids / administration & dosage
  • Clavulanic Acids / adverse effects
  • Clavulanic Acids / therapeutic use*
  • Drug Combinations
  • Female
  • Humans
  • Infant
  • Infusions, Parenteral
  • Male
  • Penicillin Resistance
  • Respiratory Tract Infections / drug therapy
  • Urinary Tract Infections / drug therapy

Substances

  • Clavulanic Acids
  • Drug Combinations
  • Amoxicillin-Potassium Clavulanate Combination
  • Amoxicillin